Improvement of nonalcoholic fatty liver disease by pig placenta extract (PPE) supplementation-Pilot study-

Effect of pig placenta extract (PPE) supplementation on nonalcoholic fatty liver disease - Pilot study -

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041210149

Enrollment

Registered

2022-02-18

Start date

2022-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

Pig placenta extract (JBP porcine 100: 350mg/capsule),orally administered 6 Capsules/day for24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Nonalcoholic fatty liver disease 2) Consent is obtained in writing 3) BMI: 25kg/m2 or more 4) Drinking amount: less than 20g/day (600g/month)

Exclusion criteria

Exclusion criteria: 1) Those who are allergic to pig placenta preparations 2) Pregnant or nursing mothers 3) Patients with severe liver disease (decompensated cirrhosis: Child-Pugh grade C, Hepatocellular carcinoma) 4) Those who cannot ingest pigs religiously 5) Patients judged by the principal investigator or sub-investigator to be inappropriate as research subjects

Design outcomes

Primary

Measure	Time frame
AST (aspartate aminotransferase) and ALT (alanine transferase) before treatment and at 12, and 24 weeks of treatment	—

Secondary

Measure	Time frame
CLDQ, BMI, type IV collagen, hyaluronic acid, CT values, and liver stiffness before and at 24 weeks of treatment	—

Contacts

Public ContactTsuchishima Mutsumi

Kanazawa Medical University Hospital

hepatol@kanazawa-med.ac.jp+81-76-218-8396

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026